Vimentin Protein In Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
01
2022
revised:
09
02
2022
accepted:
17
02
2022
entrez:
24
3
2022
pubmed:
25
3
2022
medline:
29
3
2022
Statut:
epublish
Résumé
Vimentin, a cytoplasmic intermediate filament protein, has been recently identified to be a prognostic biomarker in some cancers. However, the function of vimentin in endometrial carcinoma (EC) remains unclear. Our study aimed at evaluating vimentin expression in EC and preliminarily exploring the role of vimentin in EC progression. In total, 341 EC patients who underwent surgical follow-up were enrolled in the retrospective study. Vimentin expression levels in EC tissues were analyzed using immunohistochemistry. Furthermore, the vimentin (VIM) gene expression levels in 547 samples in The Cancer Genome Atlas (TCGA) were analyzed. To examine the prognostic value of vimentin in EC, Kaplan-Meier survival analysis was performed, and a Cox model was established. Gene set enrichment analysis (GSEA) was also conducted using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to explore the role of vimentin in EC progression. Negative vimentin expression in EC correlated significantly with lymph node metastasis, deep myometrium invasion (MI), lymph vascular space invasion (LVSI), advanced Federation International of Gynecology and Obstetrics Association (FIGO) stages (III and IV), and high tumor grade. Vimentin negativity was more common in type 2 EC than that in type 1 EC, and vimentin-negative patients had poorer overall survival compared with vimentin-positive patients. The results of GSEA suggested that vimentin may interact with classical pathways in EC. Negative vimentin expression correlates with tumor metastasis and worse overall survival in EC, suggesting that it may be an excellent prognostic biomarker for this disease. The mechanism by which vimentin contributes to EC progression needs to be explored in the future.
Sections du résumé
Background
UNASSIGNED
Vimentin, a cytoplasmic intermediate filament protein, has been recently identified to be a prognostic biomarker in some cancers. However, the function of vimentin in endometrial carcinoma (EC) remains unclear. Our study aimed at evaluating vimentin expression in EC and preliminarily exploring the role of vimentin in EC progression.
Methods
UNASSIGNED
In total, 341 EC patients who underwent surgical follow-up were enrolled in the retrospective study. Vimentin expression levels in EC tissues were analyzed using immunohistochemistry. Furthermore, the vimentin (VIM) gene expression levels in 547 samples in The Cancer Genome Atlas (TCGA) were analyzed. To examine the prognostic value of vimentin in EC, Kaplan-Meier survival analysis was performed, and a Cox model was established. Gene set enrichment analysis (GSEA) was also conducted using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to explore the role of vimentin in EC progression.
Results
UNASSIGNED
Negative vimentin expression in EC correlated significantly with lymph node metastasis, deep myometrium invasion (MI), lymph vascular space invasion (LVSI), advanced Federation International of Gynecology and Obstetrics Association (FIGO) stages (III and IV), and high tumor grade. Vimentin negativity was more common in type 2 EC than that in type 1 EC, and vimentin-negative patients had poorer overall survival compared with vimentin-positive patients. The results of GSEA suggested that vimentin may interact with classical pathways in EC.
Conclusions
UNASSIGNED
Negative vimentin expression correlates with tumor metastasis and worse overall survival in EC, suggesting that it may be an excellent prognostic biomarker for this disease. The mechanism by which vimentin contributes to EC progression needs to be explored in the future.
Identifiants
pubmed: 35320951
doi: 10.1155/2022/5240046
pmc: PMC8938074
doi:
Substances chimiques
Biomarkers, Tumor
0
VIM protein, human
0
Vimentin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5240046Informations de copyright
Copyright © 2022 Xuefang Zhang et al.
Déclaration de conflit d'intérêts
All of the authors have no relationship with companies and have no financial interest.
Références
Int J Mol Sci. 2018 Aug 17;19(8):
pubmed: 30126113
Cells. 2019 May 23;8(5):
pubmed: 31126068
Adv Exp Med Biol. 2018;1095:101-110
pubmed: 30229551
Cancer Immunol Immunother. 2020 Jun;69(6):989-999
pubmed: 32086539
Oncogene. 2016 Aug 18;35(33):4302-11
pubmed: 26751776
Cells. 2018 Sep 21;7(10):
pubmed: 30248895
FASEB J. 2018 May;32(5):2841-2854
pubmed: 29401610
Virchows Arch. 2018 Jun;472(6):885-896
pubmed: 29234950
Clin Transl Oncol. 2015 Jan;17(1):65-73
pubmed: 25028191
Mol Cell Biochem. 2018 Jan;438(1-2):47-57
pubmed: 28744809
Adv Exp Med Biol. 2020;1257:169-178
pubmed: 32483739
Lancet. 2005 Aug 6-12;366(9484):491-505
pubmed: 16084259
Small. 2019 Dec;15(50):e1903180
pubmed: 31721440
FASEB J. 2010 Jun;24(6):1838-51
pubmed: 20097873
N Engl J Med. 2020 Nov 19;383(21):2053-2064
pubmed: 33207095
Nat Rev Cancer. 2012 May 11;12(6):425-36
pubmed: 22576165
Hum Pathol. 1998 May;29(5):455-62
pubmed: 9596268
Eur J Gynaecol Oncol. 2002;23(5):411-4
pubmed: 12440813
Eur J Cancer. 1994;30A(10):1527-34
pubmed: 7833113
Mol Cancer. 2020 Jan 23;19(1):13
pubmed: 31973707
Cell Mol Life Sci. 2011 Sep;68(18):3033-46
pubmed: 21637948
Oncogene. 2011 Jan 27;30(4):457-70
pubmed: 20856200
Nan Fang Yi Ke Da Xue Xue Bao. 2016 Feb 20;37(2):157-164
pubmed: 28219857
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Commun. 2020 Oct 12;11(1):5127
pubmed: 33046716
Nat Genet. 2016 Aug;48(8):848-55
pubmed: 27348297
Bioessays. 2020 Nov;42(11):e2000078
pubmed: 32893352
Am J Surg Pathol. 1986 Aug;10(8):568-76
pubmed: 2426982
Gynecol Oncol. 1999 Jul;74(1):1-2
pubmed: 10385543
Neuro Oncol. 2002 Jul;4(3):171-8
pubmed: 12084347
Pathol Oncol Res. 2020 Jul;26(3):1411-1416
pubmed: 31811476
Exp Oncol. 2018 Oct;40(3):218-222
pubmed: 30284998
Pathol Res Pract. 2018 Sep;214(9):1376-1380
pubmed: 30078472
Cancer Res. 2006 Dec 1;66(23):11271-8
pubmed: 17145872
Mol Cancer. 2016 Feb 24;15:18
pubmed: 26905733
Small GTPases. 2011 Jan;2(1):51-53
pubmed: 21686283